Kazia Therapeutics (KZIA) Accumulated Expenses (2016 - 2025)

Kazia Therapeutics (KZIA) has 10 years of Accumulated Expenses data on file, last reported at $249768.9 in Q2 2025.

• In Q2 2025, Accumulated Expenses rose 3.84% year-over-year to $249768.9; the TTM figure through Jun 2025 stood at $249768.9 (up 3.84% YoY), while the FY2025 annual figure was $249768.9, up 3.84% from the prior year.
• Accumulated Expenses improved to $249768.9 in Q2 2025, from $240543.9 in the prior quarter.
• Across five years, Accumulated Expenses topped out at $461168.7 in Q2 2023 and bottomed at $145402.5 in Q2 2022.
• A 5-year average of $254645.3 and a median of $240543.9 in 2024 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses surged 217.17% — and 2024, when it plunged 47.84%.
• Year by year, Accumulated Expenses stood at $176342.6 in 2021, then decreased by 17.55% to $145402.5 in 2022, then surged by 217.17% to $461168.7 in 2023, then plunged by 47.84% to $240543.9 in 2024, then climbed by 3.84% to $249768.9 in 2025.
• The last three Accumulated Expenses figures came in at $249768.9 (Q2 2025), $240543.9 (Q2 2024), and $461168.7 (Q2 2023), per Business Quant data.

Peer Comparison